Effect of home-based interventions on virologic outcomes in adults receiving antiretroviral therapy in Africa: a meta-analysis. by Chishinga, Nathaniel et al.
LSHTM Research Online
Chishinga, Nathaniel; Godfrey-Faussett, Peter; Fielding, Katherine; Ayles, Helen; (2014) Effect of
home-based interventions on virologic outcomes in adults receiving antiretroviral therapy in Africa: a
meta-analysis. BMC PUBLIC HEALTH, 14 (1). ISSN 1471-2458 DOI: https://doi.org/10.1186/1471-
2458-14-239
Downloaded from: http://researchonline.lshtm.ac.uk/4652764/
DOI: https://doi.org/10.1186/1471-2458-14-239
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
RESEARCH ARTICLE Open Access
Effect of home-based interventions on virologic
outcomes in adults receiving antiretroviral
therapy in Africa: a meta-analysis
Nathaniel Chishinga1,2*, Peter Godfrey-Faussett2, Katherine Fielding3 and Helen Ayles1,2
Abstract
Background: The success of adherence to combination antiretroviral therapy (ART) in sub-Saharan Africa is
hampered by factors that are unique to this setting. Home based interventions have been identified as possible
strategies for decentralizing ART care and improving access and adherence to ART. There is need for evidence at
individual- or community-level of the benefits of home-based interventions in improving HIV suppression in African
patients receiving ART.
Methods: We conducted a systematic review and meta-analysis of the literature to assess the effect of home-based
interventions on virologic outcomes in adults receiving ART in Africa.
Results: A total of 260 publications were identified by the search strategy, 249 were excluded on initial screening
and 11 on full review, leaving 5 publications for analysis. The overall OR of virologic suppression at 12 months after
starting ART of home-based interventions to standard of care was 1.13 (95% CI: 0.51–2.52).
Conclusions: There was insufficient data to know whether there is a difference in HIV suppression at 12 months in
the home-based arm compared with the standard of care arm in adults receiving ART in Africa. Given the few trials
conducted from Africa, there is need for further research that measures the effects of home-based models on HIV
suppression in African populations.
Keywords: HIV, Virologic outcomes, Home-based interventions, Antiretroviral therapy, Meta-analysis,
Sub-Saharan Africa
Background
Successful HIV treatment programmes depend largely
on adherence of patients to combination antiretroviral
treatment (ART). Several studies have demonstrated that
adherence to ART is an important predictor of viral sup-
pression [1-4], antiretroviral resistance [1,5,6], progres-
sion to AIDS [1], and death [7,8]. However, there are
still challenges of improving adherence to ART in Africa
[9]. Home based interventions have been identified as
possible strategies of decentralizing ART care and pro-
moting task shifting to improve access and adherence to
ART. In this meta-analysis we searched for randomised
trials from Africa that used home-based strategies to im-
prove virologic outcomes in patients receiving ART to
provide evidence on the feasibility of using this interven-
tion on African populations. The reason for choosing
studies from Africa is that unlike developed countries,
the success of adherence to ART in sub-Saharan Africa
is hampered by factors that are unique to this setting.
The magnitude of HIV-related complications is becom-
ing too great for existing clinic infrastructures in Africa.
Most public health facilities in sub-Saharan Africa rely
on self-presentation of patients to the ART clinic for
group counselling on ART adherence and collection of
monthly stocks of antiretroviral drugs (ARVs). This
strategy risks failing because amidst the rapid scale-up
of ART there are severe shortages of suitably skilled
health professionals in public health facilities [10].
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Existing systematic reviews and meta-analyses on
home-based interventions [11] and directly observed
therapy for ART [12,13] have few studies from Africa.
There are significant new data from trials in Africa on
which to update these reviews. We perform a meta-
analysis on the effect of home-based interventions on vi-
rologic outcomes in adults receiving ART in Africa.
Methods
Eligibility criteria
Articles were restricted to English language and included
in this meta-analysis if they:
1. were randomised controlled trials (RCT) or cluster
randomised trials (CRT) of patients receiving ART,
because these are considered the gold standard for
assessing the effects of an intervention;
2. included virologic outcomes, and
3. reported on home-based interventions in Africa that
used either family or lay and/or professional people
to provide all forms of treatment, care or support in
the HIV-infected person’s home, as compared with
hospital or health facility-based care; even though (i)
patients still had to visit the clinic from time to time
and (ii) the clinic remained responsible for the pre-
scription of anti-retroviral regimen and changing the
therapy.
Search methods for identification of studies
The following data sources were searched in May 2010,
September 2011 and the search repeated in December 2012
for updates: PubMed/Medline from 2001 to 2012 and
EMBASE from 2001 to 2012. Additional studies not
indexed in PubMed/Medline and EMBASE were searched
from abstracts presented at the Conference on Retroviruses
and opportunistic Infections (CROI) from 2001 to 2012
and the International AIDS Society/International AIDS
(IAS/AIDS) conferences from 2000 to 2012. Also, cross
references were searched from the published systematic re-
views and meta-analyses discussed above.
The syntax and search terms were adapted from the
“Cochrane Highly Sensitive Search Strategy for identi-
fying randomised trials in PubMed/Medline: sensitivity-
maximizing version (2008 revision)” filter [14]. The search
terms for detecting randomised studies in EMBASE were
adapted from Wong and colleagues’ “Best specificity terms”
[15] (Table 1).
Data collection and analysis
Selection of studies
Search results were merged using EndNote X3 (Thomson
Reuters, TX, USA) reference manager, and duplicate re-
cords removed. The titles and abstracts of the articles were
then examined and reports that were not randomised
studies and those that were not relevant were removed.
Full-texts that were potentially relevant were then exam-
ined for compliance with eligibility criteria. Studies that did
not meet the inclusion criteria were excluded; the
remaining studies were included and data collection done.
Information obtained for each study included:
1. Study design (RCT or CRT)
2. The setting (primary or tertiary level of care) and
type of intervention (including frequency and
duration of the intervention) vs. the standard care at
the clinic.
3. The sample size of each trial
4. Characteristics of the trial participants (including
mean age distribution, gender and marital status)
5. Virologic outcomes.
Data extraction and management
The data was extracted following the search terms. The
outcome of interest for this meta-analysis was HIV sup-
pression (dichotomous outcome) in adult Africans at 12
months after starting ART. Summary data was collected
for each intervention group in a study and entered in
STATA version 11 (STATA corp., Texas, USA).
Assessment of risk of bias in included studies
The risk of bias (methodological quality) of the extracted
studies was assessed using the Cochrane Collaboration’s
‘Risk of bias’ tool [14]. This checks whether the trials re-
ported on sequence generation, allocation of concealment,
blinding, incomplete outcome data of patients lost to
follow-up (i.e., missing at follow-up as equal to virologic
failure) and other biases. The following were considered as
other biases: (i) recruitment bias; (ii) baseline imbalances.
In addition, the following were assessed in CRTs (iii) loss of
clusters; and (iv) incorrect analysis; and comparability with
individually randomised trials [14]. In CRTs, individual pa-
tient assignment of the intervention was assumed to be by
the allocation of the intervention to the cluster in which
the individuals resided. A ‘Risk of bias’ graph was then pro-
duced using RevMan version 5.0 (Copenhagen: The Nordic
Cochrane Centre, the Cochrane Collaboration, 2008).
Measures of treatment effect and unit of analysis
The measure of effect is the odds ratio (OR) of HIV sup-
pression in the home-based to the health facility-based
group. If the data in the articles was measured using rate
ratios, the rate ratio was used to estimate the OR [16].
In order to combine the effects of RCT and CRT, the
OR of HIV suppression and the 95% confidence interval
(CI) were used to calculate the log odds ratio (loge OR)
and its standard error (SE (logeOR)). Because the unit of
allocation in CRTs is a cluster, the cluster-adjusted risk
ratio and rate ratios from each CRT were used as
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estimates of cluster-adjusted OR and the loge OR and
the SE (loge OR).
Assessment of heterogeneity
The between-study heterogeneity variance of the loge
ORs, tau-squared (I2), was used to measure heterogen-
eity between trials. An I2 ≥ 30% and χ2 p-value < 0.10
were used test for evidence of heterogeneity [14]. Also, a
visual check of confidence intervals of individual studies
(depicted by horizontal lines on the forest plot) was
used; if the confidence intervals poorly overlapped, this
would indicate presence of heterogeneity.
Assessment of reporting biases
A ‘funnel plot’ of standard error vs. effect size estimate
of the intervention on virologic suppression was created
to visually assess for asymmetry as an indication of pub-
lication bias.
Data synthesis
The loge OR and SE (loge OR) for the RCTs and CRTs
were combined using the inverse-variance method for
meta-analysis in metan (STATA corp. version 11, Texas,
USA) to produce a forest plot. An OR > 1 indicated HIV
suppression favouring the home-based group. All P-
values were two sided; at 5% significance level (except in
the testing for heterogeneity where a χ2 p-value of 10%
was used as discussed above).
Sensitivity analyses
As a priori, a sensitivity analysis was going to be per-
formed only when there was evidence of heterogeneity
between studies. The sensitivity analysis would be per-
formed by including and excluding studies based on in-
dicators in the Cochrane Collaboration’s ‘Risk of bias’
tool listed above of reporting (i) sequence generation, (ii)
Table 1 Database search terms
Database Terms
PubMed/
Medline
1. Randomized controlled trial.pt.
2. Controlled clinical trial.pt.
3. Randomized.ab.
4. Placebo.ab.
5. Drugtherapy.fs.
6. Randomly.ab.
7. Trial.ab.
8. Groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. Exp animals/not humans.sh.
11. 9 not 10
12. (cluster$ adj6 randomi$).mp.
13. ((communit$ adj6 intervention$) or (communit$ adj6
randomi$)).mp.
14. group$ randomi$.mp.
15. cluster-randomi$.mp.
16. 12 or 13 or 14 or 15
17. 11 or 16
18. ((direct$ adj6 observ$) or (treat$ adj6 partner$) or
(treat$ adj6 support$) or (patient$ adj6 support$) or
(patient$ adj6 select$) or (peer adj6 health$) or (peer$
adj6 deliver$)).mp.
19. (Home based care or (facilit$ adj6 base$)).mp.
20. 18 or 19
21. Exp antiretroviral therapy, highly active/
22. Hiv treatment.mp.
23. Hiv care.mp.
24. 21 or 22 or 23
25. ((viral load) or (HIV viral load) or (virologic$ adj6 fail$)
or (virologic$ adj6 outcome$) or (treat$ adj6 fail$) or
(treat$ adj6 success$)).mp.
26. 24 or 25
27. 20 and 26
28. 17 and 27
29. Exp africa/
30. 28 and 29
EMBASE 1. Double-blind:.mp. or placebo.tw. or blind:.tw.
2. (Cluster: adj6 randomi:).mp.
3. ((communit: adj6 intervention:) or (communit: adj6
randomi:)).mp.
4. Group: randomi:.mp.
5. Cluster-randomi:.mp.
6. 2 or 3 or 4 or 5
7. 1 or 6
8. ((direct: adj6 observ:) or (treat: adj6 partner:) or (treat:
adj6 support:) or (patient: adj6 support:) or (patient: adj6
select:) or (peer adj6 health:) or (peer: adj6 deliver:)).mp.
Table 1 Database search terms (Continued)
9. (Home based care or (facility: adj6 base:)).mp.
10. 8 or 9
11. Exp antiretroviral therapy, highly active/
12. Hiv treatment.mp.
13. Hiv care.mp.
14. 11 or 12 or 13
15. ((viral load) or (HIV viral load) or (virologic: adj6 fail:)
or (virologic: adj6 outcome:) or (treat: adj6 fail:) or (treat:
adj6 success:)).mp.
16. 14 or 15
17. 10 and 16
18. 7 and 17
19. exp africa/
20. 18 and 19
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allocation of concealment, (iii) blinding, (iv) incomplete
outcome data of patients lost to follow-up (i.e., missing
at follow-up as equal to virologic failure) and (v) other
biases.
Results
Description of studies
There were 260 articles identified after using the two search
methods described above. These 260 articles included the
trials from Africa identified in the earlier meta-analyses
stated above. Out of these 260 articles, 249 were excluded
after screening by title and abstract. The remaining 11 arti-
cles were assessed for eligibility by reading through the full-
text; 5 articles were found to meet the inclusion criteria for
this meta-analysis (Figure 1).
Characteristics of included studies
Five randomised trials were included; three were RCTs
[17,35,36] and two CRTs [37,38] (Table 2). One study was
conducted in a Prevention of Mother to Child Transmis-
sion of HIV (PMTCT) programme with women only who
were attending ante-natal clinic while the rest of the studies
included men and women. All five trials reported on the ef-
fect of a home-based intervention on virologic outcomes in
adults at 12 months (48 weeks) of starting ART. The dur-
ation of the studies ranged from 12 months to 36 months.
The number of participants analysed in each study ranged
from 85 to 1 212. The combined sample size of patients
analysed was 2 688; 1 614 patients were in the intervention
(home-based) arm and 1 074 patients in the control (stand-
ard- , facility-, clinic-based) arm.
Risk of bias in included studies
The methodological qualities of the included trials were
assessed using the ‘Risk of bias’ tool (Table 3). One study
reported on blinding of study personnel, though this was
only restricted to the study pharmacist. It is not clear in the
four other studies whether laboratory personnel measuring
the viral load outcomes were blinded. Three studies ex-
cluded missing data from the analysis of virologic out-
comes. Two studies were not free of other problems that
could put them at risk of bias (trial terminated early and
contamination).
The study by Matovu and colleagues showed the highest
risk of bias because it failed to meet most of the criteria, in-
cluding lack of information on adequate allocation of con-
cealment and blinding of outcome assessment. It also
showed high risk of bias on blinding of participants and
personnel; incomplete outcome data of patients lost to
follow-up was excluded from the analysis, and ‘other biases’
of baseline imbalance in viral loads between the interven-
tion groups (Figure 2).
The proportion of studies with each of the judgements
(‘Yes’, ‘No’, ‘Unclear’) for each entry in the ‘Risk of bias’
tool were examined (Figure 3). The risk of bias in the in-
cluded studies was highest from lack of blinding of par-
ticipants and study personnel, and lowest from adequate
random sequence generation and free of selective
reporting.
Effect of intervention
The overall OR at 12 months of starting ART of home-
based to standard-based care was 1.13 (95% CI: 0.51 to
2.52, p = 0.757) (Figure 4).
Figure 1 Flow of articles selected for meta-analysis; adapted from the PRISMA statement. CROI, Conference on Retroviruses and
Opportunistic Infections. IAS, International AIDS Society/International AIDS Conference on HIV Pathogenesis, Treatment and Prevention. *Matovu,
2011 [17]. **Konate, [18]; Gusdal, [19]; Igumbor, [20]; Nglazi, [21]; Kipp, [22]; Wouters, [23]; Wouters, [24]; Shacham, [25]; Idoko, [26]; Nachega, [27];
Weidle, [28]. ‡ Naidoo, [29]. § Lester, [30]; Sarna, [31]; Fairall, [32]; Naidoo, [29]. † Stubbs, [33]; Pearson, [34].
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Table 2 Characteristics of included studies
Study Design Study
duration
Setting Inclusion and
exclusion criteria
Age Gender Sample size
analysed
Intervention Interval to
viral load
measure
HIV viral load outcomes
Jaffar
et al. [37]
Cluster
randomised
trial:
Equivalence
trial
36
months
Home and
Outpatient
clinics in
Jinja district,
Uganda
Included: 1. Patients >18
years old; 2. Starting ART for
the first time. Excluded:
Patients living 100 km away
from the ART clinic, where
the provision of the home-
based intervention was not
possible.
Mean age in
intervention
arm 37 years
(range 32–44);
Mean age in
control arm 38
years (range
33–44)
73% Female
(625/859) in
intervention
arm; 68%
Female
(406/594) in
control arm
n = 1212:
729 (22
clusters) in
intervention
arm; 483 (22
clusters) in
control arm
Intervention arm: monthly
visits to a patient’s home
by field staff to deliver ARVs
and monitor signs and
symptoms of drug toxicity
or disease progression, and
provide adherence support.
Control arm: Standard care
provided at the clinic.
Viral load
measured
at 6, 12,
18, 24,30
and 36
months
Time to RNA viral load
>500 copies/ml. “Home-
based HIV care was as
effective as was facility-
based care.”% of persons
with undetectable viral load
at 12 months in intervention
arm = (729–117)/729 =
84.0%;% of persons with
undetectable viral load at 12
months in control arm:
(483–80)/483 = 83.4%. Rate
ratio 1 · 04 (95% CI: 0 · 78 –
1 · 40; equivalence shown).
Odds Ratio = 1.04 (95%
CI: 0.78 – 1.40)§
Nachega
et al. [35]
Randomised
controlled
trial:
Superiority
trial
24
months
Home and
Public clinic
in Cape
Town, South
Africa
Included: 1. Male or non-
pregnant female ≥18 years
old; 2. HIV infection
documented by two
serologic tests; 3. Eligible
to start ART (CD4 ≤ 200
cells/μL or WHO Clinical
Stage IV disease); 4. Living
in the study site catchment
area at a stable address; 5.
Willing to disclose HIV
status to a treatment
supporter; 6. Signed
informed consent. Ex
cluded: 1. Patients with
prior ART use; 2. Life
expectancy <6 months;
3. Karnofsky Performance
Score <60; 4. Serious liver
disease; or 5. History of
single dose nevirapine for
prevention of mother to
child transmission of
HIV infection.
Mean age in
intervention
arm 35.7 years
(SD 9.7); Mean
age in control
arm 36.7 years
(SD 9.2)
57.7%
female in
intervention
arm; 57.7%
female in
control arm
n = 272:
136 in
intervention
arm; 136 in
control arm
Intervention arm: In
addition to standard care at
the clinic, trained treatment
supporters provided ART
adherence support,
observed at least one
medication dose daily and
documented it on a study
adherence chart. Control
arm: Standard care
provided at the clinic.
Viral load
measured
at 12 and
24 months
RNA viral load <400
copies/ml. “DOT-ART
showed no effect on
virologic outcomes”.% of
persons with undetectable
viral load at 12 months in
intervention arm = 99/(99 +
37) = 72.8%;% of persons
with undetectable viral load
at 12 months in control
arm = 93/(93 + 43) =
68.4%. Odds Ratio of HIV
suppression at 12
months = (99/37)/
(93/43) = 1.24 (95% CI:
0.73 – 2.09)
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Table 2 Characteristics of included studies (Continued)
Chang
et al. [38]
Cluster
randomised
trial:
Superiority
trial
48
months
Home and
Public
clinics in
rural Rakai
District,
South West
Uganda
Included: All adult patients
who were either already on
ART at the start of the trial
or were started on ART at
any time during the trial.
Mean age in
intervention
arm 35.5 years
(range 15–76);
Mean age in
control arm
34.0 years
(range 17–70)
65.8%
female in
intervention
arm; 67.5%
female in
control arm
n = 620:
456 (10
clusters) in
intervention
arm; 164 (5
clusters) in
control arm
Intervention arm:
Standard care of ARV
delivery at the clinic plus
biweekly home-based re
view by a peer health
worker who checked for
symptoms of treatment
failure; patient self-report of
adherence; pill count and
provision of counselling
and education in ART
adherence and general
HIV/AIDS-related issues.
Control arm: Standard
ART care provided at
the clinic.
Viral load
measured
at 6, 12,
18, 24,30,
36, 42, 48
months
RNA viral load >400
copies/ml. At 12 months
(48 weeks), no significant
differences were found
between the intervention
and control arm.% of
persons with undetectable
viral load at 12 months in
intervention arm =
(456–42)/456 = 90.8%;% of
persons with undetectable
viral load at 12 months in
control arm = (164–18)/164 =
89.0%. Risk Ratio 0.83 (95%
CI: 0.47 – 1.48). Odds Ratio
of HIV suppression at 12
months = 1/0.83 = 1.20
(95% CI: 0.68 – 2.13)
Taiwo
et al. [36]
Randomised
controlled
trial:
Superiority
trial
12
months
Home and
Tertiary
Hospital HIV
clinic in Jos,
Nigeria
Included: 1. HIV-1-infected;
2. Treatment-naïve; 3. Age
>15 years; 4. Eligible for
ART (clinical diagnosis of
AIDS, CD4 count <350
cells/μL with HIV-related
symptoms or CD4 count
<200 cells/μL regardless of
symptoms); 5.Willingness
and ability to select a
treatment partner.
Excluded: Patients with
severe illness.
Mean age 34.2
years (SD 8.9)
66.1%
female in
intervention
arm; 63.3%
in control
arm
n = 499:
248 in the
intervention
arm; 251 in
the control
arm
Intervention arm: In
addition to standard care
at the clinic, a treatment
partner residing in same
house or close proximity
observed the ingestion
of ARVs at least once daily.
The treatment partner
reported adverse effects
and reminded participants
of drug pick-up at the
hospital. Control arm:
Standard care provided at
the Hospital HIV clinic.
Viral load measured
at 6 and 12 months
RNA viral load <400
copies/ml. At 12 months
(48 weeks), no significant
differences were found in
HIV suppression between
the intervention and control
arm. % of persons with
undetectable viral load at
12 months in intervention
arm = 162/248 = 65.3%;% of
persons with undetectable
viral load at 12 months in
control arm = 149/251 =
59.4%. Odds Ratio = 1.28
(95% CI: 0.89 – 1.84)
Matovu
et al. [17]
Randomised
controlled
trial: Non-
inferiority
trial
12
months
Home and
PMTCT
follow-up
clinic,
Mulago
National
Referral
Hospital in
Kampala,
Uganda
Included: 1. Female; 2. Age
≥18 years; 3. Provision of
written informed consent;
4. ≥36 weeks of gestation;
5. Eligible for ART (WHO
Clinical Stage II/IV or CD4
counts <200 cells/μL); 6.
Demonstrated compliance
with ART screening visits; 7.
Residence in a stable home
within 15 km of Mulago
Hospital; 8. Willing and able
to come to the clinic
regularly without transport
reimbursement; 9. Willing
to be home visited.
Mean age in
intervention
arm 27.8 years
(SD 4.9); Mean
age in control
arm 27.0 years
(SD 5.4)
All Females n = 85: 45
in the
intervention
arm; 40 in
the control
arm
Intervention arm: Involved
peer counsellors and home
visiting, combined with nurses
providing care at routine
visits, and longer intervals
between scheduled visits.
Control arm: Standard care
provided at the Hospital
promoted adherence through
routine counselling at each
scheduled visit, care provided
by a medical officer at each
visit, and shorter intervals
between visits.
Viral load measured
at 6 and 12 months
RNA viral load <400
copies/ml.% of persons
with undetectable viral
load at 12 months was
similar in the intervention
(= 88%) and control
(= 91%) arm. Odds Ratio
of HIV suppression at
12 months = (0.88/
(1–0.88)) / (0.91/ (1–0.91)) =
0.73 (95% CI: 0.18 – 2.96)
§Jaffar et al. [37]: The rate ratio obtained from this trial was based on time to virologic failure measured over a period of 36 months in contrast to the other studies included in this search that used risk ratios or odds
ratios (OR) at 12 months. This rate ratio was reciprocated so as to change it from time to failure to time to HIV suppression. The rate ratio was reciprocated again so that the ratio is of home-based to facility-base care.
Finally this home-based to facility-based care rate ratio was used to approximate the OR of HIV suppression, which resulted in the same estimate OR of 1.04 (95% CI: 0.78 – 1.40).
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Table 3 Risk of bias in included studies
Study Adequate sequence
generated?
Allocation concealment? Blinding of participants and
personnel?
Blinding of viral load
assessment?
Incomplete outcome
data addressed?
(Missing at follow
up = treatment failure)
Free of other bias?
Jaffar
et al. [37]
Yes. Yes. No. Yes. No. Yes.
Cards were sealed in
advance and labelled
with stratum
numbers and placed
into a box
Sealed cards were drawn
from a concealed box.
The study was cluster randomized
trial; researchers and participants
knew which clusters were receiving
the interventions.
Probably done, because
Blood taken for viral load
testing was for research
purposes; the testing was
done in batches rather than
in real-time.
“Those who withdrew or
were lost to follow-up
before 12 months were
excluded from the
primary endpoint
analysis…”
The two groups were well balanced
according to baseline characteristics
apart from CD4-cell count, which was
lower in the home-based than in the
facility-based group [39]. There were
no losses of clusters. The analysis
adjusted for the effect clustering
Nachega
et al. [35]
Yes. Yes. No. Unclear. Yes. No.
Probably done,
because there was
sequential allocation
concealment
“[T]reatment assignments
were placed in opaque
envelopes, which were
sequentially opened by
the study coordinator at
enrolment.”
The study was an open-label,
randomized controlled trial; both the
researchers and the participants knew
which intervention was being
administered.
Measurement of viral loads
performed was every 6
months as part of routine
monitoring
Missing viral load values
were considered
detectable.
Trial terminated early for futility by an
independent Data and Safety
Monitoring Board
Chang
et al. [38]
Yes. Yes. No. Unclear. No. No.
An allocation
sequence was
generated
Random allocation was
by drawing of lots.
The study was cluster randomized
trial; researchers and participants
knew which clusters were receiving
the interventions.
"Viral loads … were
performed every 24 weeks
on all patients as part of
routine patient monitoring
procedures."
Those who died or were
lost to follow-up were
excluded from the
analysis of shorter-term
virologic outcomes
Contamination in the control arm was
reported in subsequent evaluation
study [40].
Taiwo
et al. [36]
Yes. Yes. Yes. No. Yes. Yes.
“Using a computer-
generated allocation
sequence,
randomization was
performed …”
Probably done, because
there was computer-
generated allocation
sequence.
“The study pharmacist, who was
blinded to treatment arm, provided
one-on-one reinforcement of the
education provided by the adherence
counsellor plus information specific
to each participant’s regimen.”
Probably not done because
patients who had detectable
viral loads at week 24
underwent intensive
adherence retraining with
the adherence counsellor.
“[P]articipants who were
missing virologic
indicators and were
reported to have died
were counted as
failures.”
There were no significant differences
between treatment groups at
baseline.
Matovu
et al. [17]
Yes. Unclear. No. Unclear. No. No.
Probably done,
because patients
were randomly
allocated.
Insufficient information
to permit judgement of
“Yes” or “No”.
The study was an open randomized
non-inferiority intervention trial.
Insufficient information to
permit judgement of “Yes”
or “No”.
Patients lost to follow-up
were excluded from the
analysis.
Baseline viral load was adjusted for.
This means there were significant
differences in viral loads between
intervention groups at baseline.
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The I2 showed no heterogeneity between trials (I2 =
0.0%, p = 0.998). Therefore no sensitivity analyses were
performed to assess differences in the studies.
Detecting publication bias
A funnel plot was used to ascertain publication bias
(Figure 5). The plot was symmetrical indicating the absence
of publication bias. The effect of the small study by Matovu
and colleagues [17] is at the bottom of the graph showing a
wide spread, while the effect of the larger study by Jaffar
and colleagues [37] is at the top of the graph showing a nar-
row spread (increased precision). The effects of all five
studies are close to the true intervention odds ratio of 1.13.
No statistical tests for funnel plot asymmetry were
performed because at least 10 studies are required to be
included in the meta-analysis for these tests to be per-
formed. When there are few studies, the power of the
tests is too low to distinguish chance from real asym-
metry [14].
Discussion
Summary of results
Neither superiority nor non-inferiority of the home-based
interventions compared with standard of care has been
clearly demonstrated with existing interventions to date.
Based on the overall 95% confidence interval in this meta-
analysis, it is conceivable that the effect of the home-based
care does lead to an almost 2-fold worse outcome of un-
suppressed HIV (OR 0.51) or that it is a lot better than the
clinic-based care (OR 2.52) - but this meta-analysis is
underpowered (by the few studies included) to demonstrate
superiority of the home-based over the clinic-based care
model. In addition, the home-based model in practice de-
pends on clinic-based activities (including laboratory tests,
monitoring of drug toxities and changing of ART regimen).
Despite one study (by Jaffar and colleagues) being an
equivalence trial, another (by Matovu and colleagues) being
a non-inferiority trial and the other three being superiority
trials, this did not affect the overall result (i.e. no evidence
of heterogeneity).
Overall completeness and applicability of evidence
The studies included in this meta-analysis were conducted
in sub-Saharan countries; where the challenge of shortages
of health workers and increased demand for care at the
clinic is apparent. Home-based interventions for ART may
Figure 2 Summary of risk of bias: judgement on each
included study.
Figure 3 Graph of risk of bias: judgement about each risk of bias item presented as percentages across all included studies.
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still have the potential of complementing existing health
facility-based care in reducing the burden of HIV care.
Home based interventions can potentially be delivered with
minimum laboratory tests at the clinic. This is substantiated
by a randomised non-inferiority trial conducted in Uganda
and Zimbabwe that demonstrated that ART can still be de-
livered safely without routine laboratory monitoring at the
clinic of toxic ART effects [41].
However, for home-based interventions to be successfully
rolled out in an African setting, there would still be need
for long-term management of HIV patients using culturally
acceptable approaches that promote adherence to ART;
that can also be easily integrated into public health models
of ART care [42]. As demonstrated by Chang and col-
leagues in 2009 and 2010 [38,43] and recently by Arem and
colleagues in 2011 [40], this can be achieved through train-
ing of HIV patients (nominated by fellow patients) to pro-
vide HIV care in homes. Consequently, this may provide
long-term benefits of adherence to ART and retention in
care [37].
Combined effect
Chang (2010, CRT)
Matovu (2011, RCT)
Nachega (2010, RCT)
Jaffar (2009, CRT)
Taiwo (2010, RCT)
1.13 (0.51, 2.52)
1.20 (0.17, 8.41)
0.73 (0.03, 19.30)
1.24 (0.19, 8.08)
1.04 (0.27, 4.06)
1.28 (0.26, 6.30)
100.0%
16.7%
5.9%
18.1%
34.3%
25.0%
First author (year of publication, study design) Odds ratio (95% CI) Weight
Heterogeneity: I-squared = 0.0%, Chi-squared = 0.12 (d.f. = 4) p = 0.998Test for combined effect: z = 0.31, p = 0.757
Favours clinic-based care Favours home-based care 
1.1 1 10
Odds ratio
Figure 4 Odds ratios of home-based to health facility-based HIV care of HIV suppression. The trials were arranged according to study
design; CRT, cluster randomized trial; RCT, Randomized controlled trial.
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Home-based vs. facility-based care trials for HIV supression from Africa
Figure 5 Funnel plot of five randomised trials comparing home-based interventions with health facility-based care in Africa. The
vertical line in the funnel plot represents the fixed effects summary estimate (using inverse-variance weighting), while the sloping lines represents
the expected 95% confidence intervals for a given standard error (assuming no heterogeneity between studies).
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Jaffar and colleagues in 2009 demonstrated that the
costs of health services for ART care is similar in the
home-based intervention and the health facility-based
group (US$793 in the home-based intervention group
and US$838 in the health facility-based group) [37].
However, for the home-based intervention to be sus-
tainable, there is need for ongoing support, training
and consistent remuneration for the home-based
workers from existing health systems [44].
Quality of the evidence
Only five trials were found to have met the study inclusion
criteria and the combined sample size analysed was 2 688.
Each study was assessed for its methodological limitation.
The study by Matovu and colleagues [17] showed the high-
est risk of bias due to failure of this study to meet most of
the criteria in the ‘Risk of bias’ assessments.
Two [35,36] of the five studies included used intention-
to-treat analyses with losses to follow-up treated as viro-
logic failures. Like most prospective studies, losses-to-
follow-up can be a source of selection bias; as it is not
known what the true outcome of those lost to follow-up is
i.e. whether they died as a result failing treatment or as a re-
sult of another competing cause of death or were still alive
at the end of follow-up but moved out of study site and
were thus not available for measuring the outcome at the
end of the study. With such losses to follow-up it was hard
to ascertain with certainty what the true outcomes were at
study completion for the patients in these trials. For ex-
ample, in the trial by Taiwo and colleagues, 14 out of 248
in the home-based group and 34 out of 251 in the health
facility-based group were not found at the end of the study
and were treated as failures [36]. These 14 losses in the
home-based group and 34 in health facility-based group
might have influenced the results differently in the Taiwo
and colleagues’ study. Also, after an evaluation of the CRT
by Chang and colleagues [38], Arem and colleagues [40]
contended that direct and indirect contamination in the
health facility-based arm could have reduced the ability of
the CRT to detect home-based intervention effects, and
may explain why no differences were seen in early virologic
outcomes between arms or in cumulative risk of virologic
outcomes. Direct contamination occurred when some pa-
tients in the health facility-based arm started volunteering
to take up tasks that were similar to those of the peer
health workers in the home-based intervention arm. Indir-
ect contamination occurred through task shifting which re-
sulted in overall gains in the quality of the ART program
during the study period [40].
Potential biases in the review process
The search for studies was performed in MEDLINE and
EMBASE. Additional articles were identified from abstracts
presented at the CROI and IAS conferences. It is likely that
all relevant articles from Africa were identified and that
there are few randomised studies that have been conducted
in Africa on the effect of home-based interventions on viro-
logic outcomes in patients receiving ART.
Agreements and disagreements with other studies or
reviews
The meta-analysis by Ford and colleagues [12] also found a
lack of effect of the directly observed ART intervention; the
risk ratio was 1.04 (95% CI: 0.91 to 1.20). As noted by Hart
and colleagues [13] this effect estimate in the study by Ford
and colleagues was smaller than their finding of RCTs des-
pite also not being significant; risk ratio 1.18 (95% CI: 0.99
to 1.42). This was also the case in this meta-analysis where
we found the overall risk OR to be higher than that of Ford
and colleagues’, though with wider 95% confidence inter-
vals; risk OR 1.13 (95% CI: 0.51 to 2.52). The reason for this
difference may be that Ford and colleagues included esti-
mates from the post intervention period; during which the
efficacy of the intervention may have waned [13], unlike in
this meta-analysis where the duration considered for the
analysis was shorter .i.e., 12 months from starting ART. If
the effects of directly observed ART intervention are not
durable .i.e., once people graduate from the directly ob-
served ART intervention there is no benefit on adherence
to ART, there may be need for directly observed ART inter-
ventions that are repetitive [45,46] or ongoing [47].
Conclusions
There was insufficient data to know whether there is
a difference in HIV suppression at 12 months in the
home-based arm compared with the standard care
arm in adults receiving ART in Africa. However,
given the high shortages of health workers in public
health facilities in Africa, home-based interventions
for ART, in addition to other approaches that have
been proven to be effective such as use of mobile
phone short message service [30,48] and use of “bud-
dies” to provide adherence support [49], may comple-
ment existing health facility-based care in reducing
the burden of care. By task shifting HIV care to peer
workers in the community that visit, provide ARVs
and witness the dosing of ARVs, adherence can be
promoted and this would not lead to poorer virologic
response to ART in African settings.
Despite a thorough literature search, only five studies
were identified to have met the inclusion criteria in this
meta-analysis. This shows that there are few randomized
trials on home-based interventions on HIV suppression
that have been conducted and reported in Africa. There
is need for further research in Africa that measures the
effects of home-based models on HIV suppression at
population level.
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